NASDAQ:KMPH - KemPharm Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.50 +0.45 (+7.44 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$6.50
Today's Range$6.15 - $6.65
52-Week Range$2.45 - $8.40
Volume176,393 shs
Average Volume142,796 shs
Market Capitalization$90.25 million
P/E Ratio-2.20
Dividend YieldN/A
Beta-0.19
KemPharm logoKemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company was founded in 2006 and is headquartered in Coralville, Iowa.

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMPH
CUSIPN/A
Phone319-665-2575

Debt

Debt-to-Equity Ratio-1.13
Current Ratio2.83
Quick Ratio2.83

Price-To-Earnings

Trailing P/E Ratio-2.20
Forward P/E Ratio-1.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($3.92) per share
Price / Book-1.66

Profitability

EPS (Most Recent Fiscal Year)($2.96)
Net Income$-43,380,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-77.95%

Miscellaneous

Employees32
Outstanding Shares15,100,000

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) released its quarterly earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($1.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.41. View KemPharm's Earnings History.

When is KemPharm's next earnings date?

KemPharm is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for KemPharm.

What price target have analysts set for KMPH?

5 brokerages have issued 12-month price objectives for KemPharm's stock. Their predictions range from $9.00 to $17.00. On average, they anticipate KemPharm's share price to reach $12.00 in the next year. View Analyst Ratings for KemPharm.

What are Wall Street analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:
  • 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (5/17/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by KemPharm’s progress with the ADHD program, and believe it represents a significant value-creating opportunity in the coming quarters. We maintain our BUY rating and $11 PT on KMPH shares. Positive IV Human Abuse Potential data bode well for upcoming ADHD reads. KemPharm announced positive results for their KP415 human abuse study, showing drug liking scores similar to placebo when administered up to the highest safest dose. There was no significant difference in mean and placebo. However, there was a numerically significant difference in mean and d-methylphenidate at equimolar doses. Drug liking is a proxy for the potential for drug abuse." (5/10/2018)

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:
  • Dr. Travis C. Mickle, Co-Founder, Pres, Chief Exec. Officer & Chairman (Age 45)
  • Mr. Daniel L. Cohen, Exec. VP of Gov. & PR (Age 59)
  • Dr. Sven Guenther Ph.D., Exec. VP of R&D (Age 46)
  • Mrs. Christal M. M. Mickle M.A., Co-Founder & VP of Operations & Product Devel. (Age 39)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 46)

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Has KemPharm been receiving favorable news coverage?

Media headlines about KMPH stock have trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. KemPharm earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.40 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are KemPharm's major shareholders?

KemPharm's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Arete Wealth Advisors LLC (3.72%), C WorldWide Group Holding A S (2.57%), Victory Capital Management Inc. (1.19%), ING Groep NV (0.92%), JPMorgan Chase & Co. (0.67%) and BlackRock Inc. (0.43%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Which major investors are selling KemPharm stock?

KMPH stock was sold by a variety of institutional investors in the last quarter, including Arete Wealth Advisors LLC, C WorldWide Group Holding A S and BlackRock Inc.. View Insider Buying and Selling for KemPharm.

Which major investors are buying KemPharm stock?

KMPH stock was acquired by a variety of institutional investors in the last quarter, including ING Groep NV, JPMorgan Chase & Co., Change Path LLC, Royal Bank of Canada, Victory Capital Management Inc. and Millennium Management LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $6.50.

How big of a company is KemPharm?

KemPharm has a market capitalization of $90.25 million. The specialty pharmaceutical company earns $-43,380,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. KemPharm employs 32 workers across the globe.

How can I contact KemPharm?

KemPharm's mailing address is 2500 CROSSPARK ROAD SUITE E126, CORALVILLE IA, 52241. The specialty pharmaceutical company can be reached via phone at 319-665-2575 or via email at [email protected]


MarketBeat Community Rating for KemPharm (KMPH)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.